The hot in vivo CAR T therapy space bubbled with news again as Johnson & Johnson (J&J) apparently forsook partner Legend Biotech Corp. and tapped Sail Biomedicines Inc. for a collaboration that will help advance the lead immune-mediated disease program as well as the broader platform technology, in a tie-up that brings incentives to expand the application of Sail's platform across more targets later.